心房动:导管切除的经济负担和影响
Nicola Pierucci1, Raffaele M Bruti2, Pietro Cipollone2
1Department of Cardiovascular, Respiratory, Nephrological, Anesthesiologic and Geriatric Sciences, Sapienza University, Rome, Italy - npierucci@gmail.com.
Minerva cardiology and angiology
|July 14, 2025
概括
导管切除 (CA) 通过减少住院治疗和医疗费用,为心房动 (AF) 管理提供长期的财务利益. 这种具有成本效益的策略可以改善药物耐药性AF患者的生活质量.
科学领域:
- 心脏病学和健康经济学
- 研究心血管疾病的经济影响和治疗疗效.
背景情况:
- 前庭动 (AF) 由于医疗保健的高利用率和成本,对全球经济造成了重大负担.
- 经常出现的AF发作加剧了全球医疗保健系统的财务压力.
- 药物治疗AF往往会带来大量的长期成本,并且可能无法完全消除症状.
研究的目的:
- 评估心房动 (AF) 的经济负担.
- 分析导管切除 (CA) 与AF的药理治疗的成本效益.
- 专注于药物耐药的AF患者,并评估长期的财务利益.
主要方法:
- 从NCBI (PubMed) 数据库中对手稿进行叙述审查.
- 分析与AF管理相关的直接和间接成本.
- 导管切除 (CA) 的成本和益处与单独的药物管理相比.
主要成果:
- 导管切除 (CA),尽管初始成本较高,但产生长期的财务效益.
- CA可以将住院率降低20-40%,急诊室的访问率降低15-30%.
- 成本效益分析表明,CA具有成本效益,每QALY的ICER在6,000-60,000美元之间,并将生活质量提高10-20%.
结论:
- 导管切除 (CA) 是一种成本效益高的策略,用于管理症状性,抗药性心房动 (AF).
- 通过减少医疗保健资源利用,CA提供了长期的经济优势.
- 该程序提供了有利的社会经济效应,包括改善患者的生活质量.
相关概念视频
01:21Cardiac Catheterization II: Right Heart Catheterization
169
Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
169
01:28Cardiac Catheterization I: Pre-Procedure Overview
167
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
167
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
54
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
54
01:26Cardiac Catheterization IV: Nursing Management
198
Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...
198
01:24Cardiac Catheterization III: Left Heart Catheterization
219
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
219
01:25Dysrhythmias VI: Management of Dysrhythmias
110
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
110